Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis-Reference-Cited by-同舟云学术

Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis

Published:2017-06-14 Issue:3 Volume:99 Page:199-206
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur J Haematol

Author:

Moreau Philippe¹^ORCID,Dimopoulos Meletios A.²,Richardson Paul G.³,Siegel David S.⁴,Cavo Michele⁵,Corradini Paolo⁶,Weisel Katja⁷,Delforge Michel⁸,O'Gorman Peter⁹,Song Kevin¹⁰,Chen Christine¹¹,Bahlis Nizar¹²,Oriol Albert¹³,Hansson Markus¹⁴,Kaiser Martin¹⁵,Anttila Pekka¹⁶,Raymakers Reinier¹⁷,Joao Cristina¹⁸,Cook Gordon¹⁹,Sternas Lars²⁰,Biyukov Tsvetan²¹,Slaughter Ana²¹,Hong Kevin²⁰,Herring Jennifer²⁰,Yu Xin²⁰,Zaki Mohamed²⁰,San-Miguel Jesus²²

Affiliation:

1. University Hospital Hôtel-Dieu; Nantes France

2. National and Kapodistrian University of Athens; Athens Greece

3. Dana-Farber Cancer Institute; Boston MA USA

4. John Theurer Cancer Center; Hackensack University Medical Center; Hackensack NJ USA

5. Bologna University School of Medicine; Bologna Italy

6. University of Milano, Fondazione IRCCS Istituto Nazionale de Tumori; Milano Italy

7. University Hospital of Tuebingen; Tuebingen Germany

8. University Hospital Leuven; Leuven Belgium

9. Mater Misericordiae University Hospital; University College Dublin; Dublin Ireland

10. Vancouver General Hospital; Vancouver British Columbia Canada

11. Princess Margaret Hospital; Toronto Ontario Canada

12. Tom Baker Cancer Center; University of Calgary; Calgary Canada

13. Institut Català d'Oncologia, Institut Josep Carreras; Hospital Germans Trias i Pujol; Barcelona Spain

14. Skane University Hospital; Lund University; Lund Sweden

15. The Royal Marsden Hospital; Surrey UK

16. Helsinki University and Helsinki University Hospital Comprehensive Cancer; Helsinki Finland

17. University Medical Center Utrecht; Utrecht The Netherlands

18. Hemato-Oncology Department; Champalimaud Foundation for the Unknown and Faculdade de Ciências Médicas-NOVA University; Lisbon Portugal

19. St James's Institute of Oncology; St James's University Hospital; Leeds UK

20. Celgene Corporation; Summit NJ USA

21. Celgene International Sàrl; Boudry Switzerland

22. Clinica Universidad de Navarra; CIMA, IDISNA; Pamplona Spain

Funder

Celgene

Publisher

Wiley

Subject

Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ejh.12903/fullpdf

Reference31 articles.

1. Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group;Laubach;Leukemia,2016

2. Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?;Thumallapally;Onco Targets Ther,2016

3. Treatment of relapsed and refractory multiple myeloma;Sonneveld;Haematologica,2016

4. Pomalidomide for multiple myeloma;Fouquet;Expert Rev Hematol,2014

5. Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma;Dimopoulos;Leukemia,2014

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Invasive fungal infections in patients with multiple myeloma: a possible growing problem in hematology and infectious diseases;Therapeutic Advances in Infectious Disease;2024-01

2. Side Effects of Treatment in Multiple Myeloma;Side Effects of Cancer Therapy;2023-10-26

3. Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial;Leukemia;2023-01-12

4. Pharmacokinetics and bioequivalence of two pomalidomide capsules in healthy chinese subjects under fasting and fed conditions;Investigational New Drugs;2022-11-28

5. Real-world Data-based Adverse Drug Reactions Analysis of Pomalidomide in Patients with Relapsed or Refractory Multiple Myeloma;Journal of Pharmacoepidemiology and Risk Management;2022-09-30